CY1117968T1 - Θεραπευτικη χρηση της πρωτεϊνης β2-μικροσφαιρινη - Google Patents

Θεραπευτικη χρηση της πρωτεϊνης β2-μικροσφαιρινη

Info

Publication number
CY1117968T1
CY1117968T1 CY20161100870T CY161100870T CY1117968T1 CY 1117968 T1 CY1117968 T1 CY 1117968T1 CY 20161100870 T CY20161100870 T CY 20161100870T CY 161100870 T CY161100870 T CY 161100870T CY 1117968 T1 CY1117968 T1 CY 1117968T1
Authority
CY
Cyprus
Prior art keywords
microsalfirin
protein
therapeutic use
beta2
microglobulin
Prior art date
Application number
CY20161100870T
Other languages
English (en)
Inventor
Marcel Mersel
Clovis Rakotoarivelo
Original Assignee
Beta Innov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Innov filed Critical Beta Innov
Publication of CY1117968T1 publication Critical patent/CY1117968T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Η παρούσα εφεύρεση αφορά τη χρήση της βήτα2-μικροσφαιρίνης (β2m) ως δραστικού συστατικού, συγκεκριμένα σε φαρμακευτικές συνθέσεις οι οποίες προορίζονται για την αγωγή αυτοάνοσων νοσημάτων.
CY20161100870T 2010-04-08 2016-09-05 Θεραπευτικη χρηση της πρωτεϊνης β2-μικροσφαιρινη CY1117968T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10290188A EP2374470A1 (fr) 2010-04-08 2010-04-08 Utilisation thérapeutique de la protéine Beta2m

Publications (1)

Publication Number Publication Date
CY1117968T1 true CY1117968T1 (el) 2017-05-17

Family

ID=42315462

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100870T CY1117968T1 (el) 2010-04-08 2016-09-05 Θεραπευτικη χρηση της πρωτεϊνης β2-μικροσφαιρινη

Country Status (20)

Country Link
US (2) US20130017212A1 (el)
EP (2) EP2374470A1 (el)
JP (3) JP5955833B2 (el)
KR (1) KR101889564B1 (el)
CN (2) CN108159398A (el)
BR (1) BR112012025537A2 (el)
CA (1) CA2793940C (el)
CY (1) CY1117968T1 (el)
DK (1) DK2555790T3 (el)
ES (1) ES2588710T3 (el)
HR (1) HRP20161022T1 (el)
HU (1) HUE030420T2 (el)
LT (1) LT2555790T (el)
PL (1) PL2555790T3 (el)
PT (1) PT2555790T (el)
RS (1) RS55121B1 (el)
RU (1) RU2582389C2 (el)
SI (1) SI2555790T1 (el)
SM (1) SMT201600301B (el)
WO (1) WO2011125029A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374470A1 (fr) * 2010-04-08 2011-10-12 Beta Innov Utilisation thérapeutique de la protéine Beta2m
CN102716379A (zh) * 2012-06-25 2012-10-10 毕建飞 一种治疗强直性脊柱炎的中药组合物
CN116515000A (zh) * 2023-06-30 2023-08-01 迦进生物医药(上海)有限公司 Hfe融合蛋白及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
JPH05506447A (ja) * 1990-05-10 1993-09-22 ザ　ダナーファーバー　キャンサー　インスチチュート β↓２―ミクログロブリンを伴い抗原供給細胞表面上で外来ペプチッドのクラスＩＭＨＣ分子との会合を増進させる方法
JPH07118163A (ja) * 1993-10-21 1995-05-09 Mitsui Toatsu Chem Inc β２−ミクログロブリンを含有する組成物
FR2735984B1 (fr) * 1995-06-30 1997-09-19 Inst Nat Sante Rech Med Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic
US6100891A (en) 1998-06-09 2000-08-08 Teledirect International, Inc. Call center agent interface and development tool
WO2001018035A2 (en) * 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
WO2002024929A2 (en) * 2000-09-22 2002-03-28 Ramot At Tel Aviv University Ltd A SOLUBLE BETA 2 MICROGLOBULIN (β2M)/HFE MONOCHAIN FOR BIOTECHNOLOGICAL AND THERAPEUTIC APPLICATIONS
GB0115071D0 (en) * 2001-06-20 2001-08-15 Avidex Ltd Substances
WO2003029475A1 (en) * 2001-09-28 2003-04-10 Dnavec Research Inc. MAMMALIAN CELL-INFECTING VIRUS VECTOR ENCODING EPITOPE-BOUND β2m AND UTILIZATION THEREOF
WO2003086307A2 (en) * 2002-04-12 2003-10-23 The Board Of Trustees Of The University Of Arkansas β2-MICROGLOBILIN (β2m) AND ANTI-β2m BINDING AGENTS AS ANTI-CANCER THERAPEUTICS
US20040127445A1 (en) 2002-08-28 2004-07-01 Chondrogene Limited Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
NZ545953A (en) 2003-09-30 2010-09-30 Snow Brand Milk Products Co Ltd Agent for promoting osteogenesis and/or inhibiting bone resorption
JP4740531B2 (ja) * 2003-09-30 2011-08-03 雪印乳業株式会社 骨吸収抑制剤
EP2374470A1 (fr) * 2010-04-08 2011-10-12 Beta Innov Utilisation thérapeutique de la protéine Beta2m
CN112303586A (zh) 2019-07-31 2021-02-02 华域视觉科技(上海)有限公司 车辆照明装置、车辆大灯及车辆

Also Published As

Publication number Publication date
KR101889564B1 (ko) 2018-08-17
WO2011125029A1 (en) 2011-10-13
RU2582389C2 (ru) 2016-04-27
EP2374470A1 (fr) 2011-10-12
KR20130086133A (ko) 2013-07-31
SI2555790T1 (sl) 2016-09-30
BR112012025537A2 (pt) 2016-06-21
JP2016145208A (ja) 2016-08-12
HUE030420T2 (en) 2017-05-29
JP2018076356A (ja) 2018-05-17
CN108159398A (zh) 2018-06-15
PL2555790T3 (pl) 2016-12-30
CA2793940C (en) 2019-07-09
EP2555790B1 (en) 2016-06-08
JP5955833B2 (ja) 2016-07-20
DK2555790T3 (en) 2016-09-12
RS55121B1 (sr) 2016-12-30
US11484571B2 (en) 2022-11-01
JP2013523808A (ja) 2013-06-17
SMT201600301B (it) 2016-11-10
PT2555790T (pt) 2016-09-09
RU2012147460A (ru) 2014-05-20
ES2588710T3 (es) 2016-11-04
EP2555790A1 (en) 2013-02-13
US20170035846A1 (en) 2017-02-09
US20130017212A1 (en) 2013-01-17
JP6703973B2 (ja) 2020-06-03
CA2793940A1 (en) 2011-10-13
LT2555790T (lt) 2016-09-12
HRP20161022T1 (hr) 2016-10-21
CN102869368A (zh) 2013-01-09

Similar Documents

Publication Publication Date Title
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1125436T1 (el) Αναστολεις dna-pk
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1122480T1 (el) Μεθυλικη βαρδοξολονη για τη θεραπεια παχυσαρκιας
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201270722A1 (ru) Формы рифаксимина и их применение
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201400735A1 (ru) Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
UY34101A (es) Proteínas de unión a antígeno
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201300558A1 (ru) Соединения и способы для купирования боли
EA201590342A1 (ru) Лечение иммуноопосредуемых и воспалительных заболеваний
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний